What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yinglian, Chen, Simiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989390/
https://www.ncbi.nlm.nih.gov/pubmed/33635318
http://dx.doi.org/10.1093/jtm/taab026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989390/
https://www.ncbi.nlm.nih.gov/pubmed/33635318
http://dx.doi.org/10.1093/jtm/taab026

Ejemplares similares